Robert Janssen - 16 Nov 2021 Form 4 Insider Report for DYNAVAX TECHNOLOGIES CORP (DVAX)

Role
Senior Vice President
Signature
/s/ Robert Janssen
Issuer symbol
DVAX
Transactions as of
16 Nov 2021
Transactions value $
-$593,701
Form type
4
Filing time
18 Nov 2021, 16:06:59 UTC
Previous filing
03 Sep 2021
Next filing
14 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DVAX Common Stock Options Exercise $377K +36K +434.68% $10.47 44.3K 16 Nov 2021 Direct
transaction DVAX Common Stock Sale -$617K -36K -81.3% $17.16 8.28K 16 Nov 2021 Direct F1
transaction DVAX Common Stock Options Exercise $559K +53.4K +645.61% $10.47 61.7K 17 Nov 2021 Direct
transaction DVAX Common Stock Sale -$912K -53.4K -86.59% $17.07 8.28K 17 Nov 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DVAX Stock Option (Right to Buy) Options Exercise -36K -34.89% 67.1K 16 Nov 2021 Common Stock 36K $10.47 Direct F3, F4
transaction DVAX Stock Option (Right to Buy) Options Exercise -53.4K -79.6% 13.7K 17 Nov 2021 Common Stock 53.4K $10.47 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $17.01 to $17.27; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax.
F2 This transaction was executed in multiple trades at prices ranging from $16.92 to $17.30; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax.
F3 This option grant will vest over three (3) years with one-third (1/3) of the shares subject to the option vesting twelve months after the grant date, and one thirty-sixth (1/36) of the shares subject to the option vesting on the last day of each month thereafter.
F4 Not applicable